SciClone Pharmaceuticals, Inc. (SCLN) said that it now expects fiscal 2009 revenues of about $72.4 million, compared to prior range of $70 million - $72 million. Analysts polled by Thomson Reuters expect the company to report revenues of $72.30 million for fiscal 2009.
Cash, cash equivalents, short and long-term investments are anticipated to be approximately $31.8 million at December 31, 2009, compared with $29.7 million at December 31, 2008.
The company expects 2010 sales revenue of $82 million to $85 million, a 15% increase over 2009. Analysts polled by Thomson Reuters expect the company to report revenues of $73.57 million for fiscal 2010.
"During 2009, we executed on our corporate strategy of managing the company as a profit-driven specialty pharmaceutical business with a strong pipeline to fuel future growth. We expect to achieve significant full year operating profitability during 2009 and are very pleased with both our commercial sales growth and cash position. Given the strong performance of our international commercial operations and careful expense management, we expect profits to continue to grow in 2010." said, Friedhelm Blobel, SciClone's President and Chief Executive Officer.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.